Overview

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Hunan Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Carboplatin
Paclitaxel